Insulin glargine

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739

Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.

Pickup, J. C., KEEN, H., PARSONS, J. A., & Alberti, K. G. M. M. (1978) · BMJ · doi:10.1136/bmj.1.6107.204 · Cited by 563

Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor

Smith, L. E. H., Shen, W., Perruzzi, C. A., Söker, S., Kinose, F., Xu, X., Robinson, G. S., Driver, S., Bischoff, J. E., Zhang, B., et al. (1999) · Nature Medicine · doi:10.1038/70963 · Cited by 555

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

Heinemann, L., Linkeschova, R., Rave, K., Hompesch, B., Sedlak, M., & Heise, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.644 · Cited by 474

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes

Ratner, R. E., Hirsch, I. B., Neifing, J. L., Garg, S. K., Mecca, T. E., & Wilson, C. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.639 · Cited by 455

Insulin analogues and their potential in the management of diabetes mellitus

Bolli, G. B., DiMarchi, R. D., Park, G. D., Pramming, S., & Koivisto, V. A. (1999) · Diabetologia · doi:10.1007/s001250051286 · Cited by 351

Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens

Jehle, P. M., Micheler, C., Jehle, D. R., Breitig, D., & Boehm, B. O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12459-5 · Cited by 185

Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor

Slieker, L. J., Brooke, G. S., DiMarchi, R. D., Flora, D. B., Green, L. K., Hoffmann, J. A., Long, H. B., Fan, L., Shields, J. E., Sundell, K. L., et al. (1997) · Diabetologia · doi:10.1007/s001250051402 · Cited by 138

The Long Acting Human Insulin Analog HOE 901: Characteristics of Insulin Signalling in Comparison to Asp(B10) and Regular Insulin

Berti, L., Kellerer, M., Bossenmaier, B., Seffer, E., Seipke, G., & Häring, H.-U. (1998) · Hormone and Metabolic Research · doi:10.1055/s-2007-978849 · Cited by 93

Diabetes: Current Perspectives

Betteridge, D. J. (1999) · Cited by 22

Insulin initiation in type 2 diabetes: What are the treatment regimen options and how can we best help patients feel empowered?

Spollett, G. R. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00721.x · Cited by 11

rDNA insulin glargine U300 – a critical appraisal

Wang, F., Zassman, S., & Goldberg, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s87873 · Cited by 11

A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: A single dose clamp study in people with type 2 diabetes

Luzio, S. D., Dunseath, G. J., Atkinson, M. D., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.002 · Cited by 10

Se‐Glargine: Chemical Synthesis of a Basal Insulin Analogue Stabilized by an Internal Diselenide Bridge

Weil‐Ktorza, O., Dhayalan, B., Chen, Y., Weiss, M. A., & Metanis, N. (2023) · ChemBioChem · doi:10.1002/cbic.202300818 · Cited by 10

Self-assembled oligomeric procyanidin–insulin hybrid nanoparticles: a novel strategy for controllable insulin delivery

Liu, R., Wang, L., Huang, R., Su, R., Qi, W. D., Yu, Y., & He, Z. (2013) · Biomaterials Science · doi:10.1039/c3bm60066a · Cited by 10

Insulin analogues: New therapies for type 2 diabetes mellitus

Bethel, M. A., & Feinglos, M. N. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0104-4 · Cited by 10

Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes

Rosenstock, J., & Owens, D. R. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.1.1 · Cited by 10

The New Insulins

Crotty, S., & REYNOLDS, S. L. (2007) · Pediatric Emergency Care · doi:10.1097/pec.0b013e31816121ba · Cited by 9

Insulin analogues

Buse, J. B. (2001) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200104000-00007 · Cited by 9

Insulinothérapie Nouvelles molécules et voies d’administration

Verge, D. (2004) · médecine/sciences · doi:10.1051/medsci/20042011986 · Cited by 8

Protected Graft Copolymer (PGC) Basal Formulation of Insulin as Potentially Safer Alternative to Lantus® (Insulin-Glargine): A Streptozotocin-Induced, Diabetic Sprague Dawley Rats Study

Reichstetter, S., Castillo, G. M., Lai, M., Nishimoto-Ashfield, A., Banerjee, A. A., Bogdanov, A. A., Jr., Lyubimov, A. V., & Bolotin, E. M. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0646-8 · Cited by 8

Management of Diabetes in Pregnancy, Childhood, and Adolescence

Unger, J. (2007) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2007.07.008 · Cited by 7

Charting the next century of insulin replacement with cell and gene therapies

Lau, H. H., Gan, S. U., Lickert, H., Shapiro, A. M. J., Lee, K., & Teo, A. K. K. (2021) · Med · doi:10.1016/j.medj.2021.09.001 · Cited by 8

Structure and pharmaceutical formulation development of a new long-acting recombinant human insulin analog studied by NMR and MS

Bednarek, E., Sitkowski, J., Bocian, W., Borowicz, P., Płucienniczak, G., Stadnik, D., Surmacz-Chwedoruk, W., Jaworska, B., & Kozerski, L. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.12.005 · Cited by 7

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

Hirose, T., Chen, C., Ahn, K. J., & Kiljanski, J. I. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0613-7 · Cited by 8

Premix insulins in type 1 diabetes: the coming of degludec/aspart

Rendell, M. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1585427 · Cited by 7

A review on the actual trends of insulin treatment in elderly with diabetes

Motta, M., Bennati, E., Ferlito, L., Passamonte, M., Cardillo, E., & Malaguarnera, M. (2007) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2007.07.009 · Cited by 8

Implantable device actuated by manual button clicks for noninvasive self‐drug administration

Kim, C. R., Cho, Y. C., Lee, S. H., Han, J. H., Kim, M. J., Ji, H. B., Kim, S., Min, C. H., Shin, B. H., Lee, C., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10320 · Cited by 5

Optimising glycaemic control — the role of long-acting insulin analogues in basal insulin therapy

Owens, D. R. (2002) · The British Journal of Diabetes · doi:10.1177/14746514020020051101 · Cited by 6

Design of Insulin Variants for Improved Treatment of Diabetes

Høeg-Jensen, T. (2009) · Wiley eBooks · doi:10.1002/9780470749708.ch7 · Cited by 6

Artificial intelligence in biologic drug discovery: A review of methodological evolution and therapeutic applications

Tang, J., Gong, D., Li, H., & Li, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.039 · Cited by 6

X-ray crystallographic and hydrogen deuterium exchange studies confirm alternate kinetic models for homolog insulin monomers

Ayan, E. B., Türk, M., Tatlı, Ö., Bostan, S., Telek, E., Dingiloğlu, B., Doğanay, G. D., Alp, M. İ., Katı, A., Doğanay, G. D., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0319282 · Cited by 5

Lipodystrophie-Erkrankungen

Miehle, K., von Schnurbein, J., Faßhauer, M., Stümvoll, M., Borck, G., & Wabitsch, M. (2017) · Medizinische Genetik · doi:10.1007/s11825-017-0162-2 · Cited by 3

Controversies in Gestational Diabetes

Zera, C., & Seely, E. W. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.102 · Cited by 9

Molecular engineering of designer diabetes therapeutics

DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5

Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée

Monnier, L., Colette, C., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00178-4 · Cited by 4

Insulin treatment of type 2 diabetes: Considerations when converting from human insulin to insulin analogs

Griffin, S. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.679959 · Cited by 4

Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy†

Fujita, N., Tsujii, S., Kuwata, H., Kurokawa, R., Matsunaga, S., Okamura, S., Mashitani, T., Furuya, M., Kitatani, M., & Ishii, H. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00164.x · Cited by 4

Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus

Sethi, B. K., Unnikrishnan, A., Ayyar, V. S., Jabbar, P. K., Ganguly, K. K., Bhandari, S., Rastogi, A., Mukherjee, R., Sundaram, V., & Asirvatham, A. R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01284-2 · Cited by 3

Hypoglycemia and insulin treatment

Febo, F., Molinari, C., & Piatti, P. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03345405 · Cited by 3

Use of new insulins in children

Regan, F. M., & Dunger, D. B. (2006) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2005.078188 · Cited by 3

PEGylated insulin Lispro (LY2605541): clinical overview of a new long-acting basal insulin analog in the treatment of Type 2 diabetes mellitus

Røder, M. E. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1043270 · Cited by 3

Des innovations technologiques au service de l’injection d’insuline

Halimi, S. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30099-8 · Cited by 3

Insight into human insulin aggregation revisited using NMR derived translational diffusion parameters

Sitkowski, J., Bocian, W., Bednarek, E., Urbańczyk, M., Koźmiński, W., Borowicz, P., Płucienniczak, G., Łukasiewicz, N., Sokołowska, I., & Kozerski, L. (2018) · Journal of Biomolecular NMR · doi:10.1007/s10858-018-0197-y · Cited by 3

Insulin Regimens for Type 1 Diabetes

Shah, B. R., & Zinman, B. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-310-1_10 · Cited by 3

Basal insulin—answers from analogues?

Barnett, A. H. (2002) · Practical Diabetes · doi:10.1002/pdi.383 · Cited by 3

Global epidemiology of type 1 diabetes in youth: 1990–2021 and projections to 2045

Zhang, K., Kan, C., Han, F., Ma, Y., Wang, Y., Li, X., Xiong, G., Chen, J., Yu, X. Q., Hou, N., et al. (2025) · Endocrine · doi:10.1007/s12020-025-04356-y · Cited by 3

Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions

Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 2

Role of insulin in management of type 2 diabetes mellitus

Patil, S. S., Mehta, M. N., Thakare, V., Shende, S. S., Shirure, P. A., & Swami, O. C. (2017) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20172422 · Cited by 2

Fibrillation of human insulin B-chain by pulsed hydrogen-deuterium exchange mass spectrometry

Renawala, H., & Topp, E. M. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.10.042 · Cited by 2

Insulin’s Legacy: A Century of Breakthroughs and Innovation

Hadid, S. A., Zhang, E., Frishman, W. H., & Brutsaert, E. F. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000680 · Cited by 2

Are our insulins more or less predictable than our patients?

Barnett, A. H., & Clarke, P. (2004) · Practical Diabetes · doi:10.1002/pdi.721 · Cited by 2

Treatment of Type 1 Diabetes Mellitus in Adults

Retnakaran, R. R., & Zinman, B. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00045-9 · Cited by 2

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes

Rendell, M. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s132581 · Cited by 2

COMPARISON OF INSULIN GLARGINE WITH HUMAN PREMIX INSULIN IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL HYPOGLYCEMIC DRUGS IN A 24-WEEK RANDOMIZED STUDY AMONG INDIAN POPULATION

Singhai, A., Banzal, S., Joseph, D., Jha, R. K., & Jain, P. (2013) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/238 · Cited by 2

Insulin and Insulin Treatment

Gough, S. C. L., & Narendran, P. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch29 · Cited by 3

Early insulin fibril detection: Insulin fibril research and TR structural transition detection with FRET-Probe

Malakoutikhah, M., Kauppi, L., Mäntylä, K., Härmä, H., & Kopra, K. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.344366 · Cited by 1

Mitochondria Function in Diabetes – From Health to Pathology – New Perspectives for Treatment of Diabetes-Driven Disorders

Łabieniec-Watała, M., Siewiera, K., Gierszewski, S., & Watal, C. (2012) · InTech eBooks · doi:10.5772/18404 · Cited by 1

Clinical Experience with Insulin Detemir: Results from the Bangladesh Cohort of Global A1chieve Study

Latif, Z. A., Pathan, M. F., Siddiqui, M. N. I., Mannan, M., Ashrafuzzaman, S., Rahman, M. M., & Sobhan, M. J. (2013) · BIRDEM Medical Journal · doi:10.3329/birdem.v3i1.17121 · Cited by 1

Genetically engineered insulin and its pharmaceutical analogues

Гусаров, Д. А., Gusarova, V. D., Bayramashvili, D. I., & Миронов, А. Ф. (2008) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750808040057 · Cited by 1

Treatment of Type 1 Diabetes Mellitus in Adults

Retnakaran, R. R., & Zinman, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00044-5 · Cited by 1

Insulin therapy: a century of continuing progress

Bolli, G. B., Fanelli, C. G., Lucidi, P., & Porcellati, F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00006-1 · Cited by 1

Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis

Zuhair, V., Obaid, M. A., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., Shakil, A., Babar, A., Rangwala, H. S., & Obaid, M. I. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01431-5 · Cited by 1

Nouvelles insulines : innovations moléculaires, galéniques et biopharmaceutiques

Chast, F. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30405-4 · Cited by 1

L'insulinothérapie au xxie siècle : une symphonie de plus en plus harmonieuse

Benhamou, P., Hanaire, H. P., & Renard, É. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00179-6 · Cited by 1

Insulin Treatment

Consoli, A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_21 · Cited by 1

Half‐Life Extension by Binding to Albumin through Small Molecules

Trüssel, S., Scheuermann, J., & Neri, D. (2012) · doi:10.1002/9783527644827.ch15 · Cited by 1

Efeito da insulina glargina sobre o controle glicêmico e risco de hipoglicemia em pacientes portadores de diabetes mellitus tipo 2 e doença renal crônica estágios 3 e 4: ensaio clínico, controlado e randomizado

Betônico, C. D. C. R. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-05042017-153224 · Cited by 1

Insulintherapie

Böhm, B. O., & Heinze, E. (2001) · Springer eBooks · doi:10.1007/978-3-642-59539-4_9 · Cited by 1

Insulin and Insulin Treatment

Vangoitsenhoven, R., Narendran, P., & Mathieu, C. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch31 · Cited by 1

Machine learning-driven risk prediction for post-hospitalization diabetes case management: Integrating clinical and social determinants of health

Lee, S.-Y., Saleem, M., Land, A. M., DeLaney, E. W., Garretson, A. R., Patel, M., Hall, A. G., Westrick, S., Ovalle, F., Cherrington, A. L., et al. (2026) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2026.106604

Conformational flexibility of the pharmacologically important insulin analogues

Ksenofontova, O., & Стефанов, В. Е. (2013) · Advances in Biological Chemistry · doi:10.4236/abc.2013.35056

Pharmacological Update on New Infusion Drugs

Wilder, G. L. (2001) · Journal of Infusion Nursing · doi:10.1097/00129804-200109000-00006

Soluble co-formulation of insulin degludec and insulin aspart: a new approach to insulin treatment

Franek, E., & Hak, Ł. (2015) · Diabetes Management · doi:10.2217/dmt.15.13

A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300

Greeff, O. B. W., van Tonder, J. J., Naidu, K., McMaster, A., van Tonder, A., & Mothilal, R. (2018) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2017.1407097

Evaluation of Unit Equivalency of Insulin Glargine to Insulin Detemir in an Acute Care Setting

Cook, E. A., Gill, T. K., & Taylor, S. (2018) · Journal of Pharmacy Technology · doi:10.1177/8755122518791265

Diabetes Drugs

Bueno, A. B., Castaño, A. M., & Rodríguez, Á. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch6

A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300

Greeff, O. B. W., van Tonder, J. J., Naidu, K., McMaster, A., van Tonder, A., & Mothilal, R. (2018) · South African Family Practice · doi:10.4102/safp.v60i4.4903

Insulin Treatment

Consoli, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_21-1

Neue Arzneimittel

Fricke, U., & Schwabe, U. (2001) · Springer eBooks · doi:10.1007/978-3-642-56434-5_2

INSULINS AND OTHER HYPOGLYCEMIC DRUGS

(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53271-8.50008-9

Promises, Promises

Hirsch, I. B. (2001) · Clinical Diabetes · doi:10.2337/diaclin.19.1.2

Insulin glargine

(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00990-6

Insulin, glucagon, and hypoglycemic drugs

Krans, H. M. J. (2002) · Side effects of drugs annual · doi:10.1016/s0378-6080(02)80049-6

Insulin glargine: 'an important milestone'?

&NA; (2000) · Inpharma Weekly · doi:10.2165/00128413-200012500-00009

Insulin glargine

(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00897-0

Fysiologische insulinetoediening

(2001) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03057785

Insulintherapie

(2006) · Springer eBooks · doi:10.1007/3-540-26602-x_8

Mapping Structural Drivers of Insulin Analogs Using Molecular Dynamics and Free Energy Calculations at Insulin ReceptorPreprint

Sena, M. M., Ramakrishnan, C., Gromiha, M. M., Chatterji, M., Khedkar, A., & Ranganathan, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.27.493461

Mapping Structural Drivers of Insulin and its Analogs at the IGF-1 Receptor Using Molecular Dynamics and Free Energy CalculationsPreprint

Sena, M. M., Ramakrishnan, C., Gromiha, M. M., Chatterji, M., Khedkar, A., & Ranganathan, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.02.569705

Advances in Pediatric Pharmacology, Therapeutics, and Toxicology

Paul, I. M., & Berlin, C. M. (2003) · Advances in Pediatrics · doi:10.1016/s0065-3101(23)00059-2

Risk Stratification for Post-Hospitalization Case Management in Diabetes: Integrating Clinical and Socioeconomic Data (Preprint)Preprint

Lee, S.-Y., Saleem, M., Land, A. M., Delaney, E. W., Garretson, A., Patel, M., Hall, A. G., Westrick, S. C., Ovalle, F., Cherrington, A., et al. (2025) · doi:10.2196/preprints.72624

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Bolli, G. B., Home, P., Lepore, M., Riddle, M. C., Porcellati, F., Fanelli, C. G., Lucidi, P., Yki‐Järvinen, H., Becker, R. H. A., & Owens, D. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70751

Damping amyloid‐associated conformational fluctuations in a protein by an engineered diselenide bridge

Yang, Y., Dhayalan, B., Ehnbom, A., Weil‐Ktorza, O., Metanis, N., & Weiss, M. A. (2026) · Protein Science · doi:10.1002/pro.70697

Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study

Bellido, V., Cuenca, A. M. C., Morales, C., Hazas, A. S. L. D. L., Soto-González, A., Morer-Liñan, C., Borrachero, J. M., Cuatrecasas, G., García, E. L., López‐Fernández, J., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01903-2

Current options in insulin therapy

Krystyník, O. (2026) · Klinická farmakologie a farmacie · doi:10.36290/far.2026.026

Insulin glargine (Aventis Pharma).

Jones, R. (2000) · PubMed · Cited by 1

Insulin glargine (Lantus), a new long-acting insulin.

(2001) · PubMed

Use of a New Long-Acting Insulin in Type 1 Diabetes

Brett, A. (2000) · Journal watch · doi:10.1056/jw200012050000004

Insulin Glargine: a review 8 years after its introduction

Goykhman, S., Drincic, A., Desmangles, J., & Rendell, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902775677 · Cited by 49

Glargine (Lantus): A new horizon ultralong basal insulin in type II diabetes along with triple drug

Premanidhi, P. (2015) · Journal of Diabetes & Metabolism